There are a number of drugs in various stages of development, including a Phase 3 trial using a treatment purchased by Celgene (NASADAQ – CELG). CELG acquired Abraxis BioScience for $2.9 billion, primarily for its Abraxane® drug which is approved for a segment of breast cancer patients and its favorable Phase 1 & 2 pancreatic cancer trial results. When used in conjunction with Eli Lilly’s Gemzar®, OS was over 1 year and the one-year survival rate was 48%.
Market Data 
Markets 
AI
